A prospective study assessing longitudinal assessment of circulating tumor mutational burden using a next-generation sequencing cancer gene panel in patients with relapsed/refractory classical hodgkin lymphoma
Latest Information Update: 30 Nov 2019
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Pharmacodynamics
Most Recent Events
- 30 Nov 2019 New trial record
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology